Latest Headlines

Latest Headlines

Bayer, J&J's Xarelto wins key FDA nod, with warning

Bayer and Johnson & Johnson ($JNJ) snagged the crucial stroke-prevention indication for their new clot-fighter Xarelto. The FDA approval isn't without its caveats, however. FDA may have granted

Dr. Reddy's strike brings police, tear gas

Dr. Reddy's says API production has been unaffected by a contract workers' strike in India over the past 80 days. But the action turned ugly on Friday when striking contractors were joined by those

FDA study: Newer contraceptives carry higher risks

New may not be better, at least when it comes to hormonal contraception. Safety data released this week not only add to the evidence that birth control pills containing a particular synthetic hormone

Strong sales from Bayer pharma, Allergan's Botox, Novo's Victoza

No fewer than 10 drug companies reported new numbers over the last 24 hours. Bayer's pharma sales are up. Allergan's Botox drug is still defying the economic crisis. Elan saw an earnings hike on the

Bayer and new partner Onyx crow over PhIII regorafenib success

Just two weeks after Bayer opted to settle a simmering legal spat with Onyx ($ONXX) over the rights to the late-stage cancer drug regorafenib, investigators published a set of positive data for the

Bayer tackles informatics challenges in cancer research

Bayer Healthcare Pharmaceuticals wants analytics that help its cancer researchers make use of ever-increasing amounts of genomic data. Working with Helsinki, Finland-based bioinformatics firm

Bayer gets $860M in Russian support for drug development/production deal

Backed with $860 million from economic development officials and a clear signal that Russia intends to play host to new biotech programs, Bayer has joined forces with a Russian company on the

Bayer to pay $160M as part of Onyx settlement

Bayer and Onyx Pharmaceuticals have resolved a longstanding dispute over the rights to a Nexavar follow-up drug. Bayer will pay $160 million plus royalties and give co-marketing rights to Onyx in

Bayer inks pledge to J.V. with Russia's Yunona

Bayer is the latest drugmaker to team up with a Russian company. The German-based conglomerate's healthcare division has inked a preliminary agreement with Yunona Holdings, which has government

Bayer settles Onyx spat with $160M payout, sales rights and royalties

Longtime partners Onyx Pharmaceuticals and Bayer have patched up a long-running dispute over who owns the rights to a Phase III cancer drug that bears a close resemblance to the blockbuster Nexavar